H.C. Wainwright analyst Vernon Bernardino initiated coverage of Windtree Therapeutics with a Neutral rating and $1 price target. The analyst is positive on istaroxime’s future prospects but neutral on the shares in the near-term. The risk/reward on Windtree shares is currently balanced based on uncertainty in lead drug istaroxime’s potential to advance into a registrational Phase 3 clinical trial, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on WINT:
- Windtree Therapeutics Announces Reduction In Arrythmias In A New Study With Istaroxime And A Pure SERCA2a Activator
- Windtree Therapeutics starts patient dosing in Phase 2 SEISMiC extension study
- Windtree Therapeutics Announces the Start of Patient Dosing In Phase 2 SEISMiC Extension Study of Istaroxime in Early Cardiogenic Shock
- Windtree Therapeutics announces issuance of pure SERCA2a activator patent
- Windtree Therapeutics Reports Third Quarter 2023 Financial Results and Provides Key Business Updates
